LBH589

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies

Conditions

Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies

Trial Timeline

May 1, 2007 → —

NCT ID

NCT00472368

About LBH589

LBH589 is a phase 1 stage product being developed by Novartis for Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00472368. Target conditions include Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies.

What happened to similar drugs?

20 of 20 similar drugs in Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01090973	Phase 2	Terminated	Mar 1, 2010	Mar 1, 2011	Non-Hodgkin's Lymphoma
NCT01007968	Phase 1	Completed	Mar 1, 2010	Nov 1, 2012	Advanced Solid Tumors
NCT01065467	Phase 1	Completed	Feb 1, 2010	Mar 13, 2017	Melanoma
NCT01013597	Phase 2	Completed	Jan 1, 2010	Feb 1, 2016	Thyroid Carcinoma
NCT01032148	Phase 1	Terminated	Dec 1, 2009	Jan 1, 2017	Hodgkin's Lymphoma
NCT01298934	Phase 1/2	UNKNOWN	Sep 1, 2009	Jul 1, 2015	Primary Myelofibrosis
NCT00939159	Phase 2	Terminated	Aug 1, 2009	Jun 1, 2013	Myelodysplastic Syndrome
NCT00936611	Phase 2	Completed	Jul 1, 2009	Nov 1, 2012	Waldenstrom's Macroglobulinemia
NCT00739414	Phase 1	Completed	Jul 1, 2008	—	Cancer
NCT00690677	Phase 2	Completed	Jun 1, 2008	Dec 1, 2011	Colorectal Cancer
NCT00532675	Phase 1	Completed	Apr 22, 2008	Nov 8, 2017	Multiple Myeloma
NCT00550277	Phase 2	Completed	Jan 1, 2008	Jun 1, 2010	Renal Cell Carcinoma
NCT00535951	Phase 1	Completed	Nov 1, 2007	—	Carcinoma, Non-Small-Cell Lung
NCT00570284	Phase 1	Completed	Nov 1, 2007	Feb 1, 2011	Cancer
NCT00532389	Phase 1	Completed	Oct 1, 2007	Oct 1, 2013	Multiple Myeloma
NCT00503451	Phase 1	Completed	Sep 1, 2007	—	Non-Hodgkin Lymphoma
NCT00472368	Phase 1	Completed	May 1, 2007	—	Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
NCT00445068	Phase 2	Terminated	Apr 16, 2007	Dec 25, 2009	Multiple Myeloma
NCT00449761	Phase 2	Terminated	Feb 23, 2007	Aug 26, 2008	Leukemia, Myeloid, Chronic
NCT00451035	Phase 2	Terminated	Feb 19, 2007	Sep 30, 2008	Chronic Myeloid Leukemia in Chronic Phase

Competing Products

20 competing products in Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies

See all competitors

Product	Company	Stage	Hype Score
mFOLFOX regimen + Mitazalimab	Alligator Bioscience AB	Phase 2/3	35
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
mRNA-2416	Moderna	Phase 2	0
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
E7389	Eisai	Phase 1	29
Veliparib	AbbVie	Phase 2	27
AK-105	Akeso	Phase 1	29
XL820	Exelixis	Phase 1	26
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
pemetrexed	Eli Lilly	Phase 2	27
LY3300054 + Prexasertib	Eli Lilly	Phase 1	29
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35